New combo therapy targets tough leukemia in adults
NCT ID NCT07454226
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for adults aged 14 to 60 with a specific, high-risk type of acute lymphoblastic leukemia called Ph-like ALL. Researchers are testing whether adding targeted drugs (olverembatinib or gecacitinib) and venetoclax to standard chemotherapy can help more patients achieve a deep remission without detectable cancer cells. The goal is to improve long-term outcomes, but patients will need ongoing treatment and monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Blood diseases hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••